Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
4.220
-0.190 (-4.31%)
At close: Apr 28, 2026, 4:00 PM EDT
4.220
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:00 PM EDT
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Aclaris Therapeutics stock have an average target of 9.80, with a low estimate of 6.00 and a high estimate of 16. The average target predicts an increase of 132.23% from the current stock price of 4.22.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 1 | 1 | 1 | 1 |
| Buy | 6 | 6 | 4 | 4 | 3 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 5 | 5 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Initiates $10 | Buy | Initiates | $10 | +136.97% | Apr 16, 2026 |
| Wedbush | Wedbush | Buy Reiterates $8 | Buy | Reiterates | $8 | +89.57% | Mar 31, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +279.15% | Mar 19, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +279.15% | Jan 28, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $16 | Strong Buy | Reiterates | $16 | +279.15% | Jan 21, 2026 |
Financial Forecast
Revenue This Year
5.14M
from 7.83M
Decreased by -34.31%
Revenue Next Year
5.36M
from 5.14M
Increased by 4.24%
EPS This Year
-0.65
from -0.53
EPS Next Year
-0.68
from -0.65
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 10.5M | 12.6M | ||||||
| Avg | 5.1M | 5.4M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 34.2% | 145.1% | ||||||
| Avg | -34.3% | 4.2% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.50 | -0.47 | ||||||
| Avg | -0.65 | -0.68 | ||||||
| Low | -0.85 | -0.76 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.